Journal
CHEMMEDCHEM
Volume 13, Issue 18, Pages 1890-1894Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.201800391
Keywords
cancer; cytotoxicity; inhibitors; SIRT2; sirtuins
Categories
Funding
- Howard Hughes Medical Institute (HHMI), Cornell University
- US National Institutes of Health (NIH)/National Institute of General Medical Sciences (NIGMS) [R01GM086703]
- NIH [S10OD018516]
- National Science Foundation (NSF) [CHE-1531632]
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM086703] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Sirtuin inhibitors have attracted much interest due to the involvement of sirtuins in various biological processes. Several SIRT2-selective inhibitors have been developed, and some exhibit anticancer activities. To facilitate the choice of inhibitors in future studies and the development of better inhibitors, we directly compared several reported SIRT2-selective inhibitors: AGK2, SirReal2, Tenovin-6, and TM. In vitro, TM is the most potent and selective inhibitor, and only TM could inhibit the demyristoylation activity of SIRT2. SirReal2, Tenovin-6, and TM all showed cytotoxicity in cancer cell lines, with Tenovin-6 being the most potent, but only TM showed cancer-cell-specific toxicity. All four compounds inhibited the anchorage-independent growth of HCT116 cells, but the effect of TM was most significantly affected by SIRT2 overexpression, suggesting that the anticancer effect of TM depends more on SIRT2 inhibition. These results not only provide useful guidance about choosing the right SIRT2 inhibitor in future studies, but also suggest general practices that should be followed for small-molecule inhibitor development activities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available